spacer
home > ebr > winter 2002 > crossbreeding and commercial consolidation in the uppsala biotech cluster
PUBLICATIONS
European Biopharmaceutical Review

Crossbreeding and Commercial Consolidation in the Uppsala Biotech Cluster

The Uppsala region has undergone a remarkable transformation in the biomedical area since the mid-1990s. The city, which lies about 70 kilometres north of the Swedish capital Stockholm, has seen a virtual explosion of research projects, business initiatives, entrepreneurial activity, new companies and industrial investment in the biotechnology and life science sectors.

Tradition, cutting edge research, access to human and financial capital, as well as a growing global market demanding solutions relying on biotech research and development, has created what has become known as the 'Uppsala Phenomenon'. "Today there are about 140 life science companies in Uppsala, of which more than 50 are biotech companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Per Odebrant, Freelance Science and Business Journalist
Per Odebrant is a Swedish freelance journalist specialising in science and business issues. He has a particular focus on applications of biotechnology, information technology and materials science. He also writes on matters concerning management, industrial organisation and intellectual capital. Per contributes to various national dailies, national and international magazines, and trade journals. He has also been a Consultant Project Manager to the Swedish Government's Information Technology Commission.
Per holds a degree in Philosophy/Linguistics from the University of Lund and has authored three novels. He was commissioned to write this article by STUNS, the Foundation for Collaboration between the Universities in Uppsala, the Business Community and Society.

spacer
Per Odebrant
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement